A Study of Guselkumab Therapy in Participants With Moderately to Severely Active Ulcerative Colitis

Фаза 3 Идёт, набор закрыт NCT05528510

Заболевание	Colitis, Ulcerative
Фаза	Фаза 3
Спонсор	Janssen Research & Development, LLC
Статус	Идёт, набор закрыт
Участники	418 участн.
Вмешательство	Guselkumab Dose 1, Guselkumab Dose 2, Guselkumab Dose 3
Дата начала	13.09.2022
Дата завершения	2.04.2024
Публикация результатов	9.12.2025

Кратко

The purpose of this study is to evaluate the efficacy, including clinical remission of guselkumab subcutaneous (SC) induction compared to placebo in participants with moderately to severely active ulcerative colitis (UC).

Percentage of Participants in Clinical Remission at Week 12

Week 12 · Percentage of participants

Placebo	6.5 Percentage of participants
Combined Guselkumab 400 mg	27.6 Percentage of participants

p-value	<0.001
Adjusted Treatment Difference	21.1 (95% CI 14.5–27.6)

Открыть в BENITIONS Открыть на ClinicalTrials.gov

Другие исследования по этому заболеванию

A Study of Guselkumab in Participants With Moderately to Severely Active Ulcerative Coliti — Janssen Research & Development, LLC
GI Permeability Change in Response to Aquamin® — James Varani
A Study to Evaluate the Efficacy and Safety of PF-06480605 in Adults With Moderate to Seve — Hoffmann-La Roche
A Study to Assess the Efficacy and Safety of Golimumab in Pediatric Participants With Mode — Janssen Research & Development, LLC
Efficacy and Mechanism of Fecal Microbiota Transplantation of the Bai Ethnicity in the Tre — First Affiliated Hospital of Kunming Medical University
ENhanced Recovery in CHildren Undergoing Surgery — Northwestern University

Все исследования

Страница обобщает открытые данные ClinicalTrials.gov. Это не медицинская и не инвестиционная рекомендация. Обратитесь к врачу.

English 한국어 日本語中文 Русский